Regorafenib + Temozolomide
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glioblastoma, IDH-wildtype
Conditions
Glioblastoma, IDH-wildtype, MGMT-Methylated Glioblastoma
Trial Timeline
Jul 4, 2022 → Dec 22, 2025
NCT ID
NCT06095375About Regorafenib + Temozolomide
Regorafenib + Temozolomide is a phase 1 stage product being developed by Bayer for Glioblastoma, IDH-wildtype. The current trial status is completed. This product is registered under clinical trial identifier NCT06095375. Target conditions include Glioblastoma, IDH-wildtype, MGMT-Methylated Glioblastoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06095375 | Phase 1 | Completed |
Competing Products
20 competing products in Glioblastoma, IDH-wildtype